BlossomHill Therapeutics, Inc.

424B4 priced

Price $16.00 · 9,375,000 shares · Gross proceeds $150,000,000

EFFECT effective

CERT inactive

8-A12B effective

S-1/A amended

Range $15.00 to $17.00 · 7,812,500 shares

BlossomHill Therapeutics, Inc. is conducting an IPO with an assumed initial public offering price of $16.00 per share. The filing details capitalization changes, including the automatic conversion of convertible preferred stock into 18,258,960 shares of common stock and the Exercised Option Share Issuance. Pro forma adjustments reflect increased cash reserves and equity, with significant dilution expected for new investors. The company plans to invest proceeds in short-term, low-risk instruments pending long-term use.

S-1 filed

BlossomHill Therapeutics, Inc. is conducting an IPO to raise capital through the sale of common stock. The filing outlines the use of net proceeds for short-term investments and details capitalization changes, including the automatic conversion of convertible preferred stock into common stock. Pro forma financial tables illustrate the impact of the offering on the company's balance sheet, with emphasis on dilution risks for new investors. The document highlights the company's historical net tangible book value deficit and potential dilution from the IPO.

DRS/A amended

DRS filed